Actively Recruiting
Signature of the Risk Profile of Mortality in a Hospital Cohort of Patients With Metabolic Diseases
Led by University Hospital, Lille · Updated on 2022-07-06
10000
Participants Needed
3
Research Sites
523 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Epidemiological studies are usually conducted in the general population in adults without complications or pathology at baseline. The results obtained are therefore often better designed for primary prevention use. The prediction of mortality risk in patients with complications and requiring hospital follow-up is less well known. The study purpose is to determine a mortality risk profile in a hospital cohort of patients with pathologies associated with metabolic diseases. Today the "multimaker" scores based on a panel of biomarkers - have significantly improved the discriminating power of prediction models existing in many pathologies. It is no longer a single biomarker that can improve risk prediction but a complete and cross-sectional profile that is sought after. We aim to establish a personalised mortality risk profile by combining clinical and biological parameters including metabolomics, genetics, transcriptomics and epigenomics by high throughput screening of biological samples.
CONDITIONS
Official Title
Signature of the Risk Profile of Mortality in a Hospital Cohort of Patients With Metabolic Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diabetic: history, treatment, or glycemia >= 1.26 g/dl, or HbA1C >= 6.5%
- Obese: BMI >= 30
- Metabolic syndrome diagnosis
- Patient has given written consent or witness consent
- Socially insured patient (excluding AME)
- Willing to comply with study procedures and duration
- Patient with at least one pathology among cardiology, neurology, diabetology, hepatology, or nephrology
- Cardiology conditions include coronary disease, heart failure, atrial fibrillation, aortic stenosis (Vmax > 2.5 m/s), or high blood pressure
- Neurology conditions include ischemic stroke, intracerebral hemorrhage, or transient ischemic attack
- Diabetology conditions include obesity without diabetes, type 2 diabetes, type 1 diabetes, monogenic diabetes/MODY, African diabetes, diabetes secondary to pancreatopathy/liver cirrhosis, diabetes post transplantation/immunotherapy, or diabetes associated with Steinert's disease
- Hepatological pathology
- Nephrology pathology
You will not qualify if you...
- Unscheduled hospitalization less than 3 months ago
- Current treatment with cytotoxic chemotherapy or radiotherapy
- HIV, hepatitis C virus (HCV), or active hepatitis B virus (HBV) infection
- OMS score of 2 or higher
- Pregnant woman
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Ch Boulogne-Sur-Mer
Boulogne-sur-Mer, France, 59037
Actively Recruiting
2
Hop Cardiologique Chr Lille
Lille, France, 59037
Actively Recruiting
3
Hop Claude Huriez Chr Lille
Lille, France, 59037
Actively Recruiting
Research Team
F
François Pattou, MD,PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here